Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice

English
0
No votes yet

Abstract

Neutralizing antibodies targeting the receptor binding domain (RBD) of the SARS-CoV-2 Spike (S) are among the most promising approaches against coronavirus disease 2019 (COVID-19)1,2. We developed a bispecific, IgG1-like molecule (CoV-X2) based on two antibodies derived from COVID-19 convalescent donors, C121 and C1353. CoV-X2 simultaneously binds two independent sites on the RBD and, unlike its parental antibodies, prevents detectable S binding to Angiotensin-Converting Enzyme 2 (ACE2), the virus cellular receptor. Furthermore, CoV-X2 neutralizes SARS-CoV-2 and its variants of concern, as well as the escape mutants generated by the parental monoclonals. In a novel animal model of SARS-CoV-2 infection with lung inflammation, CoV-X2 protects mice from disease and suppresses viral escape. Thus, simultaneous targeting of non-overlapping RBD epitopes by IgG-like bispecific antibodies is feasible and effective, combining into a single molecule the advantages of antibody cocktails.

https://www.nature.com/articles/s41586-021-03461-y

https://www.nature.com/articles/s41586-021-03461-y_reference.pdf (40MB)

Full news article in Slovak:

https://dennikstandard.sk/51773/dobra-sprava-v-cesku-uspesne-otestovali-liek-proti-vsetkym-hlavnym-mutaciam-covidu/